Scribe Therapeutics Inc. (SCTX)
Nasdaq: SCTX · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal quarter | Q3 FY26 | Q2 FY26 |
|---|---|---|
| Period ending | Sep 30, 2026 | Jun 30, 2026 |
| Report filed | Nov 12, 2026 | Sep 2, 2026 |
| Revenue | 1,636 | 1,918 |
| Research and development | 8,259 | 8,823 |
| General and administrative | 4,239 | 2,490 |
| Total operating expenses | 12,498 | 11,313 |
| Operating income | -10,862 | -9,395 |
| Interest expense | 0 | 276 |
| Total non-operating income (expense) | 1,230 | 383 |
| Income before income taxes | -9,632 | -6,265 |
| Income tax expense | 231 | 212 |
| Net income | -9,863 | -6,477 |
| Net income to common shareholders | -9,863 | · |
| Earnings per share, basic | -0.68 | -2.62 |
| Earnings per share, diluted | -0.68 | -2.62 |
| Weighted average shares, basic | 14,498,422 | 2,475,898 |
| Weighted average shares, diluted | 14,498,422 | 2,475,898 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Each quarter is three months. A fourth quarter prints only where the company tagged its three months on their own; the whole year is in the annual view.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding